Myomo Inc (MYO)vsNovartis AG ADR (NVS)
MYO
Myomo Inc
$0.86
+8.54%
HEALTHCARE · Cap: $32.00M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 138138% more annual revenue ($56.58B vs $40.93M). NVS leads profitability with a 23.9% profit margin vs -38.1%. NVS earns a higher WallStSmart Score of 51/100 (C-).
MYO
Avoid30
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+82.4%
Fair Value
$4.56
Current Price
$0.86
$3.70 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -86.2% — below average capital efficiency
Revenue declined 5.9%
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : MYO
The strongest argument for MYO centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : MYO
The primary concerns for MYO are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
MYO profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
MYO carries more volatility with a beta of 1.16 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 30/100), backed by strong 23.9% margins. MYO offers better value entry with a 82.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Myomo Inc
HEALTHCARE · MEDICAL DEVICES · USA
Myomo, Inc., a portable medical robotics company, designs, develops and produces myoelectric braces for people with neuromuscular disorders in the United States. The company is headquartered in Boston, Massachusetts.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?